Rituximab is a monoclonal antibody used to treat various conditions, including rheumatoid arthritis (RA). Here are some key points about Rituximab:
- Uses
- Treats adults with moderately to severely active RA who have had an inadequate response to TNF antagonist therapies.
- Also used for non-Hodgkin's lymphoma, Show Full Answer
Rituximab is a monoclonal antibody used to treat various conditions, including rheumatoid arthritis (RA). Here are some key points about Rituximab:
- Uses:
- Treats adults with moderately to severely active RA who have had an inadequate response to TNF antagonist therapies.
- Also used for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris.
- Mechanism:
- Works by depleting B cells, which are precursors to plasma cells that produce autoantibodies involved in RA.
- Inhibits B-lymphocyte cells, preventing them from attacking connective tissues.
- Administration:
- Given as two intravenous infusions, 15 days apart.
- Infusion usually takes 2-4 hours.
- Effects begin about six weeks after the second infusion and may last up to six months.
- Another course can be administered six months after the second infusion.
- Precautions:
- Inform your doctor if you are allergic to rituximab or any of its ingredients.
- Discuss all medications, vitamins, and supplements you are taking with your doctor.
- Efficacy:
- Shown to be safe and beneficial for RA treatment.
- Not all patients respond; initial non-responders may not benefit from repeated treatments.
- Risks:
- May affect immunization responses by dampening antibody response from new vaccinations or reducing pre-formed antibodies from prior vaccinations.
For more detailed information, you can visit the FDA website or the manufacturer's website to obtain the Medication Guide. Always consult your doctor about the risks and benefits of using Rituximab.
September 1, 2024
Continue with Facebook
Sign up with your email
